rs754532049
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_004628.5(XPC):c.1643_1644del(p.Val548AlafsTer25) variant causes a frameshift change. The variant allele was found at a frequency of 0.0000105 in 1,613,808 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000033 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000082 ( 0 hom. )
Consequence
XPC
NM_004628.5 frameshift
NM_004628.5 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 4.57
Genes affected
XPC (HGNC:12816): (XPC complex subunit, DNA damage recognition and repair factor) The protein encoded by this gene is a key component of the XPC complex, which plays an important role in the early steps of global genome nucleotide excision repair (NER). The encoded protein is important for damage sensing and DNA binding, and shows a preference for single-stranded DNA. Mutations in this gene or some other NER components can result in Xeroderma pigmentosum, a rare autosomal recessive disorder characterized by increased sensitivity to sunlight with the development of carcinomas at an early age. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 3-14158238-GCA-G is Pathogenic according to our data. Variant chr3-14158238-GCA-G is described in ClinVar as [Pathogenic]. Clinvar id is 262.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr3-14158238-GCA-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
XPC | NM_004628.5 | c.1643_1644del | p.Val548AlafsTer25 | frameshift_variant | 9/16 | ENST00000285021.12 | NP_004619.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
XPC | ENST00000285021.12 | c.1643_1644del | p.Val548AlafsTer25 | frameshift_variant | 9/16 | 1 | NM_004628.5 | ENSP00000285021 | P1 | |
XPC-AS1 | ENST00000627116.2 | n.457-7633_457-7632del | intron_variant, non_coding_transcript_variant | 5 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152098Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
5
AN:
152098
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000201 AC: 5AN: 249358Hom.: 0 AF XY: 0.0000222 AC XY: 3AN XY: 135252
GnomAD3 exomes
AF:
AC:
5
AN:
249358
Hom.:
AF XY:
AC XY:
3
AN XY:
135252
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000821 AC: 12AN: 1461710Hom.: 0 AF XY: 0.0000110 AC XY: 8AN XY: 727136
GnomAD4 exome
AF:
AC:
12
AN:
1461710
Hom.:
AF XY:
AC XY:
8
AN XY:
727136
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152098Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74282
GnomAD4 genome
AF:
AC:
5
AN:
152098
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74282
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:15Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Xeroderma pigmentosum, group C Pathogenic:7Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 10, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 01, 2009 | - - |
Pathogenic, criteria provided, single submitter | research | Medical Molecular Genetics Department, National Research Center | Dec 01, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Jan 03, 2022 | Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant (PVS1_VS). The variant has been reported at least twice as pathogenic/likely pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000000262, PMID:8298653). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000020, PM2_M). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | clinical testing | Claritas Genomics | Mar 18, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 16, 2021 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | May 22, 2020 | The XPC c.1643_1644delTG p.(Val548AlafsTer25) variant causes a shift in the protein reading frame that is predicted to result in premature termination of the protein. Loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay is expected. This variant is reported in the literature to be a founder variant in the North African population and has been reported in a homozygous state in at least 84 individuals with a phenotype consistent with xeroderma pigmentosum (Soufir et al. 2010; Sehnaji et al. 2013; Bensenouci et al. 2016). The highest frequency of this allele in the Genome Aggregation database is 0.000116 in the Admixed American population (version 2.1.1). Based on the available evidence the c.1643_1644delTG p.(Val548AlafsTer25) variant is classified as pathogenic for xeroderma pigmentosum. - |
not provided Pathogenic:5
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Apr 01, 2022 | XPC: PS4, PVS1:Strong, PM2 - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change creates a premature translational stop signal (p.Val548Alafs*25) in the XPC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in XPC are known to be pathogenic (PMID: 23173980, 25256075). This variant is present in population databases (rs754532049, gnomAD 0.009%). This premature translational stop signal has been observed in individual(s) with xeroderma pigmentosum (PMID: 20054342, 23143338, 27413738). It is commonly reported in individuals of North African ancestry (PMID: 20054342, 23143338, 27413738). ClinVar contains an entry for this variant (Variation ID: 262). For these reasons, this variant has been classified as Pathogenic. - |
Xeroderma pigmentosum Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 19, 2017 | Variant summary: The XPC c.1643_1644delTG (p.Val548AlafsX25) variant results in a premature termination codon, predicted to cause a truncated or absent XPC protein due to nonsense mediated decay, which are commonly known mechanisms for disease. One in silico tool predicts a damaging outcome for this variant. Functional studies showed absence of XPC protein expression in lymphoblasts from XP patients and reduced post-UV unscheduled DNA synthesis (Khan_2006). This variant was found in 5/246258 control chromosomes at a frequency of 0.0000203, which does not exceed the estimated maximal expected allele frequency of a pathogenic XPC variant (0.0014142). This variant is considered a founder mutation and is reported in 87% of XP-C cases from North Africa (Bensenouci_2016, El-Harith_2012, Khan_2006). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. - |
See cases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Feb 25, 2020 | ACMG classification criteria: PVS1, PS4, PM2 - |
XPC-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 21, 2023 | The XPC c.1643_1644delTG variant is predicted to result in a frameshift and premature protein termination (p.Val548Alafs*25). This variant has been frequently reported in the homozygous or compound heterozygous state in individuals with xeroderma pigmentosum group C and it is considered a founder variant in North African populations (see for example, Mahindra et al. 2008. PubMed ID: 19119101; Ben Rakaya et al. 2009. PubMed ID: 19478817; Soufir et al. 2010. PubMed ID: 20054342; Santiago et al. 2020. PubMed ID: 32239545; Rabie et al. 2021. PubMed ID: 33672602). In vitro functional studies also support its pathogenicity (Schäfer et al. 2013. PubMed ID: 23173980). This variant is reported in 0.012% of alleles in individuals of Latino descent in gnomAD. Frameshift variants in XPC are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at